Clinical characteristics and outcomes of posttransplant lymphoproliferative disorders following allogeneic hematopoietic stem cell transplantation in Korea.

Journal of Korean Medical Science
Sun Hee ParkChun Choo Kim

Abstract

Between 1995 and 2003, seven cases of posttransplant lymphoproliferative disorder (PTLD) were identified among 1,116 patients who received allogeneic hematopoietic stem cell transplantations (HSCT) at Catholic HSCT Center (overall incidence 0.6%). Five (71.4%) patients had episodes of acute graft-versus-host-disease (GVHD) and were treated with steroids. Cervical lymphadenopathy was observed in most cases (71.4%), but clinical symptoms varied depending on the involved sites. Pathologic findings varied: 1 case of plasmacytic hyperplasia, 3 of polymorphic PTLD, 2 of diffuse large B-cell lymphoma, 1 of large T-cell lymphoma, which proved to be associated with Epstein-Barr virus (EBV). The proportion of EBV-negative PTLD was 33.3%. Five patients demonstrated a good response to treatment (treatment response rate 71.4%). The overall mortality was 42.8%, and one death was directly attributable to PTLD. The incidence of PTLD is expected to increase, based on the rising use of grafts from alternative donors and recent clinical features of PTLD manifested by a disseminated and fulminant nature. It is necessary to have a high level of suspicion when monitoring patients and readily adopt prompt and effective cellular immunotherapy for PTLD.

References

Dec 1, 1990·American Journal of Clinical Pathology·M M ZutterE D Thomas
Jan 1, 1994·The American Journal of Surgical Pathology·D W KingmaE S Jaffe
Feb 10, 1998·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·D H DockrellC V Paya
Jun 17, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·V LeblondM Raphael
Mar 15, 2000·The American Journal of Surgical Pathology·B P NelsonS H Swerdlow
Aug 17, 2000·The New England Journal of Medicine·J I Cohen
Jun 9, 2001·Transplant Infectious Disease : an Official Journal of the Transplantation Society·M A Nalesnik
Aug 24, 2001·International Journal of Oral and Maxillofacial Surgery·S X Hong, C K Yi
Aug 16, 2002·British Journal of Haematology·Karin C M StraathofCliona M Rooney
Mar 7, 2003·Bone Marrow Transplantation·A W LorenD E Tsai
Mar 27, 2004·The New England Journal of Medicine·David A Thorley-Lawson, Andrew Gross
Oct 9, 2004·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Jutta K Preiksaitis
Jan 22, 2005·Annual Review of Medicine·Stephen GottschalkHelen E Heslop

❮ Previous
Next ❯

Methods Mentioned

BETA
biopsy
MDS

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.